Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Lenvatinib plus Pembrolizumab und Chemotherapie versus Chemotherapie bei fortgeschrittenem metastasiertem gastroösophagealem Adenokarzinom: die randomisierte Phase-III-Studie LEAP-015
Journal of Clinical Oncology · 2025-08 · 43 (22) · 2502-2514
DOI: 10.1200/jco-25-00748 ↗Auf einen Blick
In der Phase-III-Studie verbesserte Lenvatinib plus Pembrolizumab plus Chemotherapie das progressionsfreie Überleben gegenüber Chemotherapie. Ein Überlebensvorteil zeigte sich bei PD-L1-CPS ≥1 nicht.
Fragestellung
Verbessert Lenvatinib plus Pembrolizumab und Chemotherapie im Vergleich zu Chemotherapie das progressionsfreie Überleben und das Gesamtüberleben beim fortgeschrittenen metastasierten gastroösophagealen Adenokarzinom?
Methode
Randomisierte, offene Phase-III-Studie; 18 Jahre und älter mit unbehandeltem HER2-negativem lokal fortgeschrittenem, nicht resektablem oder metastasiertem gastroösophagealem Adenokarzinom; 1:1-Randomisierung.
Ergebnisse
880 Teilnehmende: 443 mit Lenvatinib plus Pembrolizumab, 437 mit Chemotherapie. PFS bei PD-L1-CPS ≥1: 7,3 vs. 6,9 Monate; HR 0,75 (95 %-KI 0,62–0,9). In allen Teilnehmenden: 7,2 vs. 7,0 Monate; HR 0,78 (95 %-KI 0,66–0,92).
Einschränkungen
Die Autoren berichten, dass die klinische Bedeutung des PFS-Unterschieds begrenzt erscheint.
Schlussfolgerung der Autor:innen
Lenvatinib plus Pembrolizumab und Chemotherapie führte im Vergleich zu Chemotherapie zu einer statistisch signifikanten PFS-Verbesserung in der Interimsanalyse; beim OS in PD-L1-CPS ≥1 zeigte sich kein signifikanter Vorteil.
Kernaussagen
- PFS war unter der Kombination statistisch signifikant besser als unter Chemotherapie.
- OS bei PD-L1-CPS ≥1 war nicht signifikant verbessert.
- Unerwünschte Ereignisse Grad ≥3: 65 % vs. 49 %.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-08. Verfasst von Kohei Shitara und 26 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Quinolines, Stomach Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710 ) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adenocarcinoma. METHODS Eligible participants 18 years and older with untreated human epidermal growth factor receptor 2–negative locally advanced unresectable or metastatic gastroesophageal adenocarcinoma were randomly assigned 1:1 to induction with oral lenvatinib 8 mg once daily plus pembrolizumab 400 mg intravenously once every 6 weeks (×2) and investigators’ choice of capecitabine and oxaliplatin once every 3 weeks (×4) or fluorouracil, leucovorin, and oxaliplatin once every 2 weeks (×6) and consolidation with lenvatinib plus pembrolizumab, or chemotherapy. Dual primary end points were progression-free survival (PFS) and overall survival (OS) in participants with PD-L1 combined positive score (CPS) ≥1 and all participants. Secondary end points included objective response rate (ORR) and duration of response. RESULTS Of 880 participants randomly assigned, 443 received lenvatinib plus pembrolizumab and 437 received chemotherapy. The median follow-ups were 32.2 months (range, 19.0-41.7) in participants with PD-L1 CPS ≥1 and 31.8 months (19.0-41.7) in all participants. At interim analysis, PFS was statistically significant with lenvatinib plus pembrolizumab versus chemotherapy in participants with PD-L1 CPS ≥1 (median, 7.3 v 6.9 months; hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.9]; P = .0012) and all participants (median, 7.2 v 7.0 months; HR, 0.78 [95% CI, 0.66 to 0.92]; P = .0019). The ORR was 59.5% versus 45.4% in participants with PD-L1 CPS ≥1 and 58.0% versus 43.9% in all participants, P < .0001 for both. At final analysis, OS was not statistically significant in participants with PD-L1 CPS ≥1 (median, 12.6 v 12.9 months; HR, 0.84 [95% CI, 0.71 to 1.00]; P = .0244; P value boundary = .0204). Grade ≥3 drug-related adverse event rates were 65% versus 49%. CONCLUSION Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy provided a statistically significant improvement in PFS in advanced unresectable or metastatic gastroesophageal carcinoma at interim analysis although the clinical significance of this difference seems to be limited. No significant improvement occurred in OS in participants with PD-L1 CPS ≥1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Hematology and Oncology, Technical University of Munich, Munich, Germany.
- Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Hematology and Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Hemato Oncólogo, IMAT-Oncomedica, Montería, Colombia.
- Medi-K Cayala Treatment Center, Cayala/Universidad Francisco Marroquin, Guatemala City, Guatemala.
ORCID-Profile: Kohei Shitara, Hirokazu Shoji, Luis Corrales, Lucjan Wyrwicz, Min-Hee Ryu, Zev A Wainberg, Geoffrey Ku, Josep Tabernero, Eric Van Cutsem, Do-Youn Oh, Jianming Xu, Sonal Bordia, Sun Young Rha
Förderung
- NCI NIH HHS
Zitieren
APA
Shitara, K., Lorenzen, S., Li, J., Bai, Y., Fernández, M. G., Aguilar, M., Shoji, H., Reyes-Cosmelli, F., Peña, Y. R., Corrales, L., Wyrwicz, L., Eyzaguirre, D. A., Pan, Y., Ryu, M. H., Cohen, D. J., Wainberg, Z. A., Ku, G., Tabernero, J., Van Cutsem, E., …, & LEAP-015 Investigators (2025). Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. Journal of Clinical Oncology, 43(22), 2502-2514. https://doi.org/10.1200/jco-25-00748
Vancouver
Shitara K, Lorenzen S, Li J, Bai Y, Fernández MG, Aguilar M, et al. Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. Journal of Clinical Oncology. 2025;43(22):2502-2514. doi:10.1200/jco-25-00748
BibTeX
@article{Shitara2025,
author = {Shitara, Kohei and Lorenzen, Sylvie and Li, Jin and Bai, Yuxian and Fernández, Manuel González and Aguilar, Mynor and Shoji, Hirokazu and Reyes-Cosmelli, Felipe and Peña, Yovany Rodriguez and Corrales, Luis and Wyrwicz, Lucjan and Eyzaguirre, Daniel Acosta and Pan, Yueyin and Ryu, Min-Hee and Cohen, Deirdre J and Wainberg, Zev A and Ku, Geoffrey and Tabernero, Josep and Van Cutsem, Eric and Qin, Shu-Kui and Oh, Do-Youn and Xu, Jianming and Liang, Li Wen and Bordia, Sonal and Bhagia, Pooja and Rha, Sun Young and LEAP-015 Investigators, LEAP-015 Investigators},
title = {Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {22},
pages = {2502--2514},
doi = {10.1200/jco-25-00748}
}
EUVIMED